[Recombinant human erythropoietin (rHuEPO) in the treatment of primary hemochromatosis].
Martín Núñez
G
G
Fernández Galán
M
M
López López
R
R
González Hurtado
J
J
D000328:Adult; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D004921:Erythropoietin / Q000627:therapeutic use*; D005492:Folic Acid / Q000627:therapeutic use; D006680:HLA Antigens / Q000235:genetics; D006432:Hemochromatosis / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I / Q000235:genetics; D006801:Humans; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D020125:Mutation, Missense; D018962:Phlebotomy; D011994:Recombinant Proteins
C103673:HFE protein, human; D006680:HLA Antigens; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I; D008565:Membrane Proteins; D011994:Recombinant Proteins; D004921:Erythropoietin; D005492:Folic Acid